Home › NDC Lookup › RxCUI directory › RxCUI 1801514

Methylnaltrexone bromide 150 MG Oral Tablet — RxCUI 1801514

RxNorm drug concept · Semantic clinical drug
RxCUI 1801514 Semantic clinical drug · SCD ● Current RxNorm concept 3 FDA products 6 package NDCs Snapshot Jul 14, 2026

This page is curated, coded, and maintained by

Compiled from public NLM RxNorm and FDA (openFDA NDC directory) data sources. Editorial policy

What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.

🗂️ Key Facts

RxCUI1801514
Official nameMethylnaltrexone bromide 150 MG Oral Tablet
Concept typeSemantic clinical drug (SCD)
RxNorm statusCurrent RxNorm concept
Also known asmethylnaltrexone bromide 150 MG (equivalent to methylnaltrexone 122.5 MG) Oral Tablet
FDA products mapped3
Package NDCs mapped6
Reported Medicaid activity (SDUD)18,616 prescriptions · 35 state & territory Medicaid programs · latest period Q4 2025
RxNorm release07/06/2026
Snapshot dataJul 14, 2026

📖 Skip the Codes — Read It in Plain English.

Our pharmacist-built guide to Methylnaltrexone Injection: what it is, how it’s used, side effects, and interactions.

📗 Our plain-language guide HelloPharmacist
  • No — that's actually the key feature of this medicine. Relistor is designed to work only in your gut, not in your brain. It blocks opioid receptors in the digestive tract to reliev...
  • Will Relistor injection reduce the effectiveness of my pain medication?
  • Relistor is absorbed into your system quite quickly after a subcutaneous injection — it reaches peak levels in your blood within about 15 to 30 minutes. Many people find they need...
  • How soon after the injection should I expect results?
📖 Read our full Methylnaltrexone Injection guide →

🕸️ Concept Web — How Methylnaltrexone bromide 150 MG Oral Tablet Connects

One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.
This page's concept Methylnaltrexone bromide 150 MG Oral Tablet RxCUI 1801514

Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.

  1. Ingredients 2

    The active substance itself — no strength, form, or brand attached yet.

    • Methylnaltrexone 29899
    • Methylnaltrexone bromide 979111
  2. Brand names 1

    The same medicine's trade names. A brand name alone says nothing about strength or form.

    • Relistor 796436
  3. Dose forms 13

    The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.

    • Methylnaltrexone Oral Tablet 1801513
    • Methylnaltrexone bromide Oral Tablet 2647260
    • Methylnaltrexone Oral Product 1801511
    • Methylnaltrexone Pill 1801512
    • Methylnaltrexone bromide Oral Product 2659219
    • Methylnaltrexone bromide Pill 2660338
    • Methylnaltrexone Oral Tablet [Relistor] 1801516
    • Methylnaltrexone bromide Oral Tablet [Relistor] 2657231
    • +5 more in this family
  4. Clinical & branded drugs 3

    Ingredient + strength + dose form. These are the concepts real FDA products actually carry.

Showing up to 8 concepts per family — 14 of 19 stored related concepts drawn.
These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.

🔀 Generic ⇄ Brand Crosswalk

The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.

Generic (Clinical) Concepts

  • Methylnaltrexone bromide 150 MG SCDC · 1801510
  • Methylnaltrexone Oral Tablet SCDF · 1801513
  • Methylnaltrexone bromide Oral Tablet SCDFP · 2647260
  • Methylnaltrexone Oral Product SCDG · 1801511
  • Methylnaltrexone Pill SCDG · 1801512
  • Methylnaltrexone bromide Oral Product SCDGP · 2659219
  • Methylnaltrexone bromide Pill SCDGP · 2660338

Brand-Name Concepts

  • Methylnaltrexone bromide 150 MG Oral Tablet [Relistor] SBD · 1801519
  • Methylnaltrexone bromide 150 MG [Relistor] SBDC · 1801515
  • Methylnaltrexone Oral Tablet [Relistor] SBDF · 1801516
  • Methylnaltrexone bromide Oral Tablet [Relistor] SBDFP · 2657231
  • Relistor Oral Product SBDG · 1801517
  • Relistor Pill SBDG · 1801518
  • Relistor BN · 796436

📦 FDA Products & Package NDCs

3 products · 6 package NDCs
6 package NDCs map to RxCUI 1801514 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.
Package NDC Package Brand / generic name Labeler Marketing start
65649-0150-06 1 BOTTLE in 1 CARTON (65649-150-06) / 6 TABLET in 1 BOTTLE Relistor Salix Pharmaceuticals, Inc. 2016-07-19
65649-0150-90 90 TABLET in 1 BOTTLE (65649-150-90) Relistor Salix Pharmaceuticals, Inc. 2016-07-19
65649-0551-02 1 VIAL, SINGLE-DOSE in 1 CARTON (65649-551-02) / .6 mL in 1... Relistor Salix Pharmaceuticals, Inc. 2008-04-24
65649-0551-03 7 BLISTER PACK in 1 CARTON (65649-551-03) / 1 SYRINGE in 1... Relistor Salix Pharmaceuticals, Inc. 2008-04-24
65649-0551-07 1 BLISTER PACK in 1 CARTON (65649-551-07) / 1 SYRINGE in 1... Relistor Salix Pharmaceuticals, Inc. 2008-04-24
65649-0552-04 7 BLISTER PACK in 1 CARTON (65649-552-04) / 1 SYRINGE in 1... Relistor Salix Pharmaceuticals, Inc. 2008-04-24
Observed labelers: Salix Pharmaceuticals, Inc. (6) — this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.

🗃️ Sources & Limits

Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7
openFDA export observedJul 14, 2026
RxNorm release07/06/2026
Methodology2026-07-full-catalog-v1
  • A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
  • Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
  • Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
  • Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.

Machine-readable JSON

Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.